Generic Zegerid Availability

Zegerid is a brand name of omeprazole/sodium bicarbonate, approved by the FDA in the following formulation(s):

ZEGERID (omeprazole; sodium bicarbonate - capsule; oral)

  • Manufacturer: SANTARUS
    Approval date: February 27, 2006
    Strength(s): 20MG;1.1GM [AB], 40MG;1.1GM [RLD] [AB]

ZEGERID (omeprazole; sodium bicarbonate - for suspension; oral)

  • Manufacturer: SANTARUS
    Approval date: June 15, 2004
    Strength(s): 20MG/PACKET;1.68GM/PACKET [AB]
  • Manufacturer: SANTARUS
    Approval date: December 21, 2004
    Strength(s): 40MG/PACKET;1.68GM/PACKET [RLD] [AB]

Has a generic version of Zegerid been approved?

A generic version of Zegerid has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zegerid and have been approved by the FDA:

OMEPRAZOLE AND SODIUM BICARBONATE (omeprazole; sodium bicarbonate capsule; oral)

  • Manufacturer: PAR PHARM
    Approval date: May 25, 2010
    Strength(s): 20MG;1.1GM [AB], 40MG;1.1GM [AB]

OMEPRAZOLE AND SODIUM BICARBONATE (omeprazole; sodium bicarbonate for suspension; oral)

  • Manufacturer: PAR PHARM
    Approval date: April 19, 2013
    Strength(s): 20MG/PACKET;1.68GM/PACKET [AB], 40MG/PACKET;1.68GM/PACKET [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zegerid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Omeprazole solution and method for using same
    Patent 5,840,737
    Issued: November 24, 1998
    Inventor(s): Phillips; Jeffrey Owen
    Assignee(s): The Curators of the University of Missouri
    A pharmaceutical composition includes an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier comprising a bicarbonate salt of a Group IA metal. A method for treating and/or preventing gastrointestinal conditions by administering to a patient a pharmaceutical composition including an aqueous solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof in a pharmaceutically acceptable carrier including a bicarbonate salt of a Group IA metal wherein the administering step consists of a single dosage form without requiring further administering of the bicarbonate salt of the Group IA metal. A pharmaceutical composition for making a solution/suspension of omeprazole or other substituted benzimidazoles and derivatives thereof includes omeprazole or other substituted benzimidazoles and derivatives thereof and a bicarbonate salt of a Group IA metal in a form for convenient storage whereby when the composition is dissolved in aqueous solution, the resulting solution is suitable for enteral administration.
    Patent expiration dates:
    • July 16, 2016
      ✓ 
      Patent use: SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
    • July 16, 2016
      ✓ 
      Patent use: REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
    • July 16, 2016
      ✓ 
      Patent use: SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
  • Substituted benzimidazole dosage forms and method of using same
    Patent 6,489,346
    Issued: December 3, 2002
    Inventor(s): Jeffrey Owen; Phillips
    Assignee(s): The Curators of the University of Missouri
    There is provided a solid pharmaceutical composition in a dosage form that is not enteric-coated, having active ingredients including a non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor is omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form includes a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition.
    Patent expiration dates:
    • July 16, 2016
      ✓ 
      Patent use: SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • July 16, 2016
      ✓ 
      Patent use: REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • July 16, 2016
      ✓ 
      Patent use: SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Substituted benzimidazole dosage forms and method of using same
    Patent 6,645,988
    Issued: November 11, 2003
    Inventor(s): Jeffrey O.; Phillips
    Assignee(s): Curators of the University of Missouri
    The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical dosage form that is not enteric coated or delayed released containing a proton pump inhibitor and a Primary Essential Buffer. When the dosage form is placed in a liquid phase the Primary Essential Buffer maintains the pH of the environment at a value greater than the pKa of the proton pump inhibitor for a time sufficient to substantially avoid acid degradation of the proton pump inhibitor in the environment. Also provided is a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical dosage form; and a kit for the preparation of a liquid oral pharmaceutical composition.
    Patent expiration dates:
    • July 16, 2016
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Substituted benzimidazole dosage forms and methods of using same
    Patent 6,699,885
    Issued: March 2, 2004
    Inventor(s): Jeffrey O.; Phillips
    Assignee(s): The Curators of the University of Missouri
    Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.
    Patent expiration dates:
    • July 16, 2016
      ✓ 
      Patent use: SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
    • July 16, 2016
      ✓ 
      Patent use: SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER
    • July 16, 2016
      ✓ 
      Patent use: REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
  • Substituted benzimidazole dosage forms and method of using same
    Patent 6,780,882
    Issued: August 24, 2004
    Inventor(s): Jeffrey O.; Phillips
    Assignee(s): The Curators of the University of Missouri
    There is provided a solid pharmaceutical composition having active ingredients that include at least one non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor, for example, omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, is present in an amount of approximately 5 mg to approximately 300 mg; and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form can be non-enteric coated and can be in the form of a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition of the present invention.
    Patent expiration dates:
    • July 16, 2016
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Substituted benzimidazole dosage forms and method of using same
    Patent 7,399,772
    Issued: July 15, 2008
    Inventor(s): Phillips; Jeffrey Owen
    Assignee(s): Curators of the University of Missouri
    The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical composition consisting of a proton pump inhibitor and at least one buffering agent. Also provided is a pharmaceutical composition further comprising a parietal cell activator, an anti-foaming agent, a flavoring agent and combinations thereof; a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical composition; and, a kit for the preparation of a liquid oral pharmaceutical composition. Dosage forms include: liquid, powder, tablet, capsule, effervescent powder, effervescent tablet, pellets, and granules.
    Patent expiration dates:
    • July 16, 2016
      ✓ 
      Patent use: SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS
    • July 16, 2016
      ✓ 
      Patent use: REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS
    • July 16, 2016
      ✓ 
      Patent use: SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER

See also...

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Trouble with Ulcerative Colitis? Learn about treatments to alleviate symptoms. Click Here

Close
(web5)